Apoptosis-inducer-52-生命科学试剂-MCE

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemEApoptosisinducer52Cat.No.:HY-179124分⼦式:C₂₂H₁₅F₆N₃O₂Se分⼦量:546.32作⽤靶点:Apoptosis;Caspase作⽤通路:Apoptosis储存⽅式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY⽣物活性Apoptosisinducer52⼀种氟他胺的衍⽣物，在前列腺癌细胞中诱导凋亡(apoptosis)。Apoptosisinducer52通过激活内性和外性凋亡途径促进细胞凋亡，且不产⽣活性氧(ROS)。Apoptosisinducer52触发caspase3/7活性，并使磷脂酰丝氨酸外翻，导致细胞周期在G0/G1期停滞。Apoptosisinducer52可⽤于雄激素受体(AR)依赖性和⾮依赖性前列腺癌和⽩⾎病的研究。IC50&TargetCaspase3Caspase-7Caspase-8Caspase-9体外研究Apoptosisinducer52(compouna5)(1-100μM;48h;LNCaP)inhibitsLNCaPandnonmalignantHaCaTcellswithIC50valuesof8.89µMand28.71ꢀµM,respectively[1].

Apoptosisinducer52displaysaremarkableantiproliferativeactivitytowardtheK-562celllinefromthe

leukemiasubpanel[1].Apoptosisinducer52(10μM;24-48h;LNCaP)inducesapoptosisinatime‐dependent.[1].Apoptosisinducer52(10μM;48h;LNCaP)arrestscellcycleinG0/G1phase[1].Apoptosisinducer52(10μM;48h;LNCaP)increasesexpressionofcaspase3,8,9andupregulatesBAX[1].Apoptosisinducer52(10μM;12-24h;LNCaP)marginallyincreasesROSproduction.TheresultsuggestthatapoptosisinductionbyApoptosisinducer52maybeROS-independent[1].CellViabilityAssay[1]CellLine:LNCaPandHaCaTcellsConcentration:1,2.5,5,10,25,50,100μM1/2MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemEIncubationTime:48hResult:Cellviabilitydecreasedinadose-dependentmanner.ApoptosisAnalysis[1]CellLine:LNCaPConcentration:10μMIncubationTime:24,48hResult:Theratioofapoptoticcellsincreasedsignificantlyattheendofthe48ꢀh.Caspase3/7activityincreasedandphosphatidylserineexternalizationwasobserved.CellCycleAnalysis[1]CellLine:LNCaPConcentration:10μMIncubationTime:48hResult:InhibitedthecellcycleprogressionbyarrestingthecellsintheG0/G1phase.WesternBlotAnalysis[1]CellLine:LNCaPConcentration:10μMIncubationTime:48hResult:Expressionlevelsofpro-caspase3,pro-caspase9,caspase3,caspase9,caspase8increased,andBAXlevelswereupregulated.REFERENCES[1].Morán-SerradillaC,etal.InnovativeSe-FlutamideDerivatives:EnhancedActivityTowardAndrogenReceptor(AR)-Dependentand-IndependentProstateCancerCells.ArchPharm(Weinheim).2025;358(10):e70119.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forre